JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Decitabine promotes the differentiation of poorly differentiated gastric cancer cells and enhances the sensitivity of NK cell cytotoxicity via TNF-α

  • 0School of Life Science, Tianjin University, Tianjin, 300072, China.
Scientific Reports +

|

April 16, 2025

|

April 16, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Decitabine (DAC) reduces poorly differentiated gastric cancer (PDGC) cell proliferation and invasion. DAC also enhances cancer cell sensitivity to Natural Killer (NK) cell attacks by upregulating immune-related genes like tumor necrosis factor alpha (TNF-α).

Area Of Science

  • Oncology
  • Cancer Biology
  • Immunology

Background

  • Poorly differentiated gastric cancer (PDGC) exhibits aggressive behavior and poor patient outcomes.
  • Differentiation therapy offers a promising strategy to inhibit tumor growth with fewer side effects.
  • Decitabine (DAC), a DNA methylation inhibitor, can induce cellular differentiation by reactivating silenced genes.

Purpose Of The Study

  • To investigate the effects of Decitabine (DAC) on the proliferation, migration, and invasion of PDGC cell lines.
  • To evaluate DAC's impact on PDGC cell sensitivity to Natural Killer (NK) cell-mediated cytotoxicity.
  • To explore the underlying molecular mechanisms, including the role of immune-related gene expression.

Main Methods

  • Treatment of PDGC cell lines (MKN45, NUGC4) with DAC.
  • Assessment of cell proliferation, migration, and invasion.
  • Transcriptomic analysis to identify gene expression changes.
  • Co-culture experiments with NK cells and PDGC cells.
  • In vivo studies using subcutaneous tumor implantation in nude mice.

Main Results

  • DAC treatment significantly reduced PDGC cell proliferation, migration, and invasion without affecting cell viability.
  • Transcriptomic analysis revealed upregulation of immune-related genes, including tumor necrosis factor alpha (TNF-α), in DAC-treated cells.
  • DAC enhanced PDGC cell sensitivity to NK cell-mediated cytotoxicity, with TNF-α playing a key role.
  • In vivo, DAC administration inhibited tumor growth and upregulated differentiation-related genes.

Conclusions

  • Decitabine effectively reduces the malignant characteristics of PDGC cells by promoting differentiation.
  • DAC enhances PDGC cell susceptibility to NK cell-mediated killing, partly through TNF-α upregulation.
  • This study provides insights into the antitumor mechanisms of DAC in PDGC, suggesting its potential as a therapeutic agent.

Keywords:

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists 01:28

137

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...

Targeted Cancer Therapies 02:57

7.4K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine 02:50

4.8K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy 01:27

400

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drugs that Stabilize Microtubules 01:15

1.9K

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...